The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
Open accessAbstract
BACKGROUND: Planning for outbreaks of influenza is a high priority public health issue for national governments. Neuraminidase inhibitors (NIs) are thought to help reduce the symptoms of influenza with several possible mechanisms proposed. NIs have been stockpiled with a view to their widespread use in the event of a pandemic. However, the evidence base for this class of agents remains a source of debate. In a previous review we have documented substantial risks of publication bias of trials of NIs for influenza (60% of patient data from phase III treatment trials of oseltamivir have never been published) and reporting bias in the published trials. Our confidence in the conclusions of previous versions of this review has been subsequently undermined. Since we have become aware of a large number of unpublished trials of NIs in the management of influenza, this review updates and merges existing reviews in this area. OBJECTIVES: To review clinical study reports of placebo-controlled randomised trials, regulatory comments and reviews ('regulatory information') of the effects of the NIs oseltamivir and zanamivir for influenza in all age groups and appraise trial programmes, rather than single studies.Clinical study reports are very detailed, unpublished clinical trial data containing in-depth descriptions of protocol rationale, methods analysis plans, trial results and organisational documents (such as contracts). A series of clinical studies designed and conducted by one sponsor represents a trial programme of a drug indication (for example treatment of influenza). SEARCH METHODS: We searched trial registries, cross-referencing published and unpublished sources and corresponded with manufacturers and regulators. We searched the archives of the US Food and Drug Administration (FDA) and European and Japanese regulators. The evidence in this review reflects searches to obtain relevant information up to 12 April 2011. SELECTION CRITERIA: We included regulatory information based on assessments of randomised controlled trials (RCTs) conducted in people of any age who had either confirmed or suspected influenza, or who had been exposed to influenza in the local community or place of residence. We included information which had been made available by our deadline. DATA COLLECTION AND ANALYSIS: We indexed regulatory information in two purpose-built instruments and reconstructed trials using CONSORT statement-based templates. To progress to Stage 2 (full analysis) we sought manufacturer explanations of discrepancies in the data. GlaxoSmithKline (GSK) offered us individual patient data and responded to our queries, but Roche did not provide us with complete clinical study reports. In Stage 2 we intended to analyse trials with validated data (i.e. assuming our validation questions aimed at clarifying omissions and discrepancies were resolved). No studies progressed to Stage 2. We carried out analyses of the effects of oseltamivir on time to first alleviation of symptoms and hospitalisations using the intention-to-treat (ITT) population and tested five hypotheses generated post-protocol publication. MAIN RESULTS: We included and analysed data from 25 studies (15 oseltamivir and 10 zanamivir studies). We could not use data from a further 42 studies due to insufficient information or unresolved discrepancies in their data. The included trials were predominantly conducted in adults during influenza seasons in both hemispheres. A small number of studies were conducted in older people residing in care homes and in people with underlying respiratory diseases. The studies had adequate randomisation and blinding procedures, but imbalances in the analysis populations available (ITT influenza-infected) left many of the studies at risk of attrition bias. All the studies were sponsored by manufacturers of NIs. Time to first alleviation of symptoms in people with influenza-like illness symptoms (i.e. ITT population) was a median of 160 hours (range 125 to 192 hours) in the placebo groups and oseltamivir shortened this by around 21 hours (95% confidence interval (CI) -29.5 to -12.9 hours, P < 0.001; five studies) but there was no evidence of effect on hospitalisations based on seven studies with a median placebo group event rate of 0.84% (range 0% to 11%): odds ratio (OR) 0.95; 95% CI 0.57 to 1.61, P = 0.86). These results are based on the comprehensive ITT population data and are unlikely to be biased. A post-protocol analysis showed that participants randomised to oseltamivir in treatment trials had a reduced odds being diagnosed with influenza (OR 0.83; 95% CI 0.73 to 0.94, P = 0.003; eight studies), probably due to an altered antibody response. Zanamivir trials showed no evidence of this. Due to limitations in the design, conduct and reporting of the trial programme, the data available to us lacked sufficient detail to credibly assess a possible effect of oseltamivir on complications and viral transmission. We postponed analysis of
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Dooley, L., Hama, R., & Heneghan, C. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001265.pub2 · Cited by 226
Self-citationRetractedCochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
(2001) · PsycEXTRA Dataset · doi:10.1037/e548312006-001 · Cited by 5,011
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
(2008) · Cited by 3,790
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Harpaz, R., Ortega‐Sanchez, I. R., & Seward, J. F. (2008) · Cited by 1,302
Avian Influenza A (H5N1) Infection in Humans
(2005) · New England Journal of Medicine · doi:10.1056/nejmra052211 · Cited by 1,285
Neuraminidase Inhibitors for Influenza
Moscona, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050740 · Cited by 1,094
In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses
Itoh, Y., Shinya, K., Kiso, M., Watanabe, T., Sakoda, Y., Hatta, M., Muramoto, Y., Tamura, D., Sakai-Tagawa, Y., Noda, T., et al. (2009) · Nature · doi:10.1038/nature08260 · Cited by 1,073
Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kinnersley, N., Ward, P., Mills, R. G., et al. (2000) · JAMA · doi:10.1001/jama.283.8.1016 · Cited by 1,014
Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection
de Jong, M. D., Thanh, T. T., Khanh, T. H., Hien, V. M., Smith, G. J. D., Chau, N. V., Cam, B. V., Qui, P. T., Ha, D. Q., Guan, Y., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa054512 · Cited by 901
Publication bias in clinical trials due to statistical significance or direction of trial results
Hopewell, S., Loudon, K., Clarke, M. J., Oxman, A. D., & Dickersin, K. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000006.pub3 · Cited by 898
Vaccines for preventing influenza in healthy adults
Jefferson, T., Di Pietrantonj, C., Rivetti, A., Bawazeer, G. A., Al-Ansary, L. A., & Ferroni, E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001269.pub4 · Cited by 896
Self-citationKoopmans, M., Wilbrink, B., Conyn, M., Natrop, G., van der Nat, H., Vennema, H., Meijer, A., van Steenbergen, J., Fouchier, R., Osterhaus, A., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15589-x · Cited by 837
Prevention and Control of Influenza: Recommendation of the Immunization Practices Advisory Committee
(1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-4-560 · Cited by 810
Physical interventions to interrupt or reduce the spread of respiratory viruses
Jefferson, T., Del Mar, C. B., Dooley, L., Ferroni, E., Al-Ansary, L. A., Bawazeer, G. A., van Driel, M. L., Nair, N. S., Jones, M. A., Thorning, S., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006207.pub4 · Cited by 805
Self-citationResistant influenza A viruses in children treated with oseltamivir: descriptive study
Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., Hayden, F. G., Sugaya, N., & Kawaoka, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16934-1 · Cited by 786
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial
Nicholson, K., Aoki, F., Osterhaus, A., Trottier, S., Carewicz, O., Mercier, C., Rode, A., Kinnersley, N., & Ward, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02288-1 · Cited by 785
Hayden, F. G., Osterhaus, A. D. M. E., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., Bohnen, A. M., Hirst, H. M., Keene, O., & Wightman, K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371302 · Cited by 762
Fiore, A. E., Fry, A. M., Shay, D. K., Gubareva, L. V., Bresee, J., & Uyeki, T. M. (2011) · PubMed · Cited by 761
Oral oseltamivir treatment of influenza in children
WHITLEY, R. J., HAYDEN, F. G., REISINGER, K. S., YOUNG, N., DUTKOWSKI, R., IPE, D., MILLS, R. G., & WARD, P. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200102000-00002 · Cited by 711
Containing Pandemic Influenza with Antiviral Agents
Longini, I. M. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh092 · Cited by 705
Matrosovich, M. N., Matrosovich, T. Y., Gray, T., Roberts, N. A., & Klenk, H.-D. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12665-12667.2004 · Cited by 606
Industry sponsorship and research outcome
Lundh, A., Sismondo, S., Lexchin, J., Busuioc, O. A., & Bero, L. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub2 · Cited by 605
Eyding, D., Lelgemann, M., Grouven, U., Harter, M., Kromp, M., Kaiser, T., Kerekes, M. F., Gerken, M., & Wieseler, B. (2010) · BMJ · doi:10.1136/bmj.c4737 · Cited by 588
Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review
Jefferson, T., Del Mar, C., Dooley, L., Ferroni, E., Al-Ansary, L. A., Bawazeer, G. A., van Driel, M. L., Foxlee, R., & Rivetti, A. (2009) · BMJ · doi:10.1136/bmj.b3675 · Cited by 562
Self-citationHayden, F. G., Treanor, J. J., Fritz, R. S., Lobo, M., Betts, R. F., Miller, M., Kinnersley, N., Mills, R. G., Ward, P., & Straus, S. E. (1999) · JAMA · doi:10.1001/jama.282.13.1240 · Cited by 550
Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza
Hayden, F. G., Atmar, R. L., Schilling, M., Johnson, C., Poretz, D., Paar, D., Huson, L., Ward, P., & Mills, R. G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910283411802 · Cited by 512
Kaiser, L., Wat, C., Mills, T., Mahoney, P., Ward, P., & Hayden, F. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.14.1667 · Cited by 501
Katz, J. D., Hancock, K., Veguilla, V., Zhong, W., Lü, X., Sun, H., Butler, E. N., Dong, L., Liu, F., Li, Z. N., et al. (2009) · MMWR Morbidity and Mortality Weekly Report · Cited by 499
(2004) · PsycEXTRA Dataset · doi:10.1037/e548622006-001 · Cited by 471
Welliver, R. (2001) · JAMA · doi:10.1001/jama.285.6.748 · Cited by 463
Reporting bias in medical research - a narrative review
McGauran, N., Wieseler, B., Kreis, J., Schüler, Y.-B., Kölsch, H., & Kaiser, T. (2010) · Trials · doi:10.1186/1745-6215-11-37 · Cited by 452
Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic
Ward, P., Small, I., Smith, J., Suter, P., & Dutkowski, R. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki018 · Cited by 428
Early administration of oral oseltamivir increases the benefits of influenza treatment
Aoki, F. Y. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg007 · Cited by 424
Human Illness from Avian Influenza H7N3, British Columbia
Tweed, S. A., Skowronski, D. M., David, S. T., Larder, A., Petric, M., Lees, W., Li, Y., Katz, J., Krajden, M., Tellier, R., et al. (2004) · Emerging Infectious Diseases · doi:10.3201/eid1012.040961 · Cited by 382
Inhaled Zanamivir for the Prevention of Influenza in Families
Hayden, F. G., Gubareva, L. V., Monto, A. S., Klein, T. C., Elliott, M. J., Hammond, J. M., Sharp, S. J., & Ossi, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431801 · Cited by 371
Liu, C., Eichelberger, M. C., Compans, R. W., & Air, G. M. (1995) · Journal of Virology · doi:10.1128/jvi.69.2.1099-1106.1995 · Cited by 367
Jefferson, T., Jones, M., Doshi, P., & Del Mar, C. (2009) · BMJ · doi:10.1136/bmj.b5106 · Cited by 363
Self-citationOutcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use
Vedula, S. S., Bero, L., Scherer, R. W., & Dickersin, K. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0906126 · Cited by 361
Cooper, N. J., Sutton, A. J., Abrams, K. R., Wailoo, A., Turner, D., & Nicholson, K. G. (2003) · BMJ · doi:10.1136/bmj.326.7401.1235 · Cited by 357
(1998) · The Lancet · doi:10.1016/s0140-6736(98)10190-3 · Cited by 351
Does This Patient Have Influenza?
Call, S. A. (2005) · JAMA · doi:10.1001/jama.293.8.987 · Cited by 345
Hayden, F. G., Belshe, R., Villanueva, C., Lanno, R., Hughes, C., Small, I., Dutkowski, R., Ward, P., & Carr, J. (2004) · The Journal of Infectious Diseases · doi:10.1086/381128 · Cited by 334
Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov
Bourgeois, F. T., Murthy, S., & Mandl, K. D. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-3-201008030-00006 · Cited by 332
Zanamivir in the Prevention of Influenza Among Healthy Adults: A Randomized Controlled Trial
Monto, A. S., Robinson, D. P., Herlocher, M. L., Hinson, Jr., Elliott, M. J., & Crisp, A. (1999) · JAMA · doi:10.1001/jama.282.1.31 · Cited by 321
Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe
Lackenby, A., Hungnes, O., Dudman, S. G., Meijer, A., Paget, W. J., Hay, A. J., & Zambon, M. C. (2008) · Eurosurveillance · doi:10.2807/ese.13.05.08026-en · Cited by 318
Influenza and COPD Mortality Protection as Pleiotropic, Dose-Dependent Effects of Statins
Frost, F. J., Petersen, H., Tollestrup, K., & Skipper, B. (2007) · Chest · doi:10.1378/chest.06-1997 · Cited by 302
Joining the DoTS: new approach to classifying adverse drug reactions
Aronson, J. K., & Ferner, R. E. (2003) · BMJ · doi:10.1136/bmj.327.7425.1222 · Cited by 297
Monto, A. S., Fleming, D. M., Henry, D., de Groot, R., Makela, M., Klein, T., Elliott, M., Keene, O. N., & Man, C. Y. (1999) · The Journal of Infectious Diseases · doi:10.1086/314904 · Cited by 275
Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?
Hayden, F. (2009) · Clinical Infectious Diseases · doi:10.1086/591851 · Cited by 256
Mendel, D. B., Tai, C. Y., Escarpe, P. A., Li, W., Sidwell, R. W., Huffman, J. H., Sweet, C., Jakeman, K. J., Merson, J., Lacy, S. A., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.3.640 · Cited by 255
Turner, D., Wailoo, A., Nicholson, K., Cooper, N., Sutton, A., & Abrams, K. (2003) · Health Technology Assessment · doi:10.3310/hta7350 · Cited by 246
HEDRICK, J. A., BARZILAI, A., BEHRE, U., HENDERSON, F. W., HAMMOND, J., REILLY, L., & KEENE, O. (2000) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200005000-00005 · Cited by 245
Cass, L. M. R., Efthymiopoulos, C., & Bye, A. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936001-00001 · Cited by 227
Prevention and early treatment of influenza in healthy adults
Demicheli, V (2000) · Vaccine · doi:10.1016/s0264-410x(99)00332-1 · Cited by 211
Fritz, R. S., Hayden, F. G., Calfee, D. P., Cass, L. M. R., Peng, A. W., Alvord, W. G., Strober, W., & Straus, S. E. (1999) · The Journal of Infectious Diseases · doi:10.1086/314938 · Cited by 207
Long‐Term Use of Oseltamivir for the Prophylaxis of Influenza in a Vaccinated Frail Older Population
Peters, P. H., Gravenstein, S., Norwood, P., De Bock, V., Van Couter, A., Gibbens, M., Von Planta, T., & Ward, P. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.49204.x · Cited by 190
Sugaya, N., & Ohashi, Y. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01755-09 · Cited by 183
Mäkelä, M. J., Pauksens, K., Rostila, T., Fleming, D. M., Man, C. Y., Keene, O. N., & Webster, A. (2000) · Journal of Infection · doi:10.1053/jinf.1999.0602 · Cited by 180
Neuraminidase inhibitors for preventing and treating influenza in children
Matheson, N. J., Harnden, A., Perera, R., Sheikh, A., & Symmonds-Abrahams, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002744.pub2 · Cited by 180
Roles of neuraminidase in the initial stage of influenza virus infection
Ohuchi, M., Asaoka, N., Sakai, T., & Ohuchi, R. (2006) · Microbes and Infection · doi:10.1016/j.micinf.2005.12.008 · Cited by 173
Human infection by avian influenza A H5N1.
Yuen, K., & Wong, S. S. Y. (2005) · PubMed · Cited by 168
Shun-Shin, M., Thompson, M., Heneghan, C., Perera, R., Harnden, A., & Mant, D. (2009) · BMJ · doi:10.1136/bmj.b3172 · Cited by 167
Self-citationToovey, S., Rayner, C., Prinssen, E., Chu, T., Donner, B., Thakrar, B., Dutkowski, R., Hoffmann, G., Breidenbach, A., Lindemann, L., et al. (2008) · Drug Safety · doi:10.2165/0002018-200831120-00006 · Cited by 165
The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience
Doshi, P., Jefferson, T., & Del Mar, C. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001201 · Cited by 165
Self-citationMonto, A. S., Webster, A., & Keene, O. N. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.suppl_2.23 · Cited by 153
Monto, A. S., Pichichero, M. E., Blanckenberg, S. J., Ruuskanen, O., Cooper, C., Fleming, D., & Kerr, C. (2002) · The Journal of Infectious Diseases · doi:10.1086/345722 · Cited by 148
Challenges in Systematic Reviews That Assess Treatment Harms
Chou, R., & Helfand, M. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_2-200506211-00009 · Cited by 145
Tappenden, P., Jackson, R., Cooper, K. L., Rees, A., Simpson, E. L., Read, R. C., & Nicholson, K. G. (2009) · Health Technology Assessment · doi:10.3310/hta13110 · Cited by 139
Science, Politics, and the Pharmaceutical Industry: Controversy and Bias in Drug Regulation
Lindee, S., & Abraham, J. M. (1998) · Technology and Culture · doi:10.2307/3107068 · Cited by 136
Calfee, D. P., Peng, A., Cass, L., Lobo, M., & Hayden, F. G. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1616 · Cited by 135
Wieseler, B., Wolfram, N., McGauran, N., Kerekes, M. F., Vervölgyi, V., Kohlepp, P., Kamphuis, M., & Grouven, U. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001526 · Cited by 133
Controversies concerning randomization and additivity in clinical trials.
Senn, S. (2004) · Statistics in Medicine · doi:10.1002/sim.2074 · Cited by 132
Pharmacoscintigraphic Evaluation of Lung Deposition of Inhaled Zanamivir in Healthy Volunteers
Cass, L., Brown, J., Pickford, M., Fayinka, S. T., Newman, S. P., Johansson, C. J., & Bye, A. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936001-00003 · Cited by 132
Barroso, L. F., Treanor, J. J., Gubareva, L. V., & Hayden, F. G. (2005) · Antiviral Therapy · doi:10.1177/135965350501000805 · Cited by 127
Developing efficient search strategies to identify reports of adverse effects in medline and embase
Golder, S., McIntosh, H. M., Duffy, S., & Glanville, J. (2006) · Health Information & Libraries Journal · doi:10.1111/j.1471-1842.2006.00634.x · Cited by 124
Does Influenza Transmission Occur from Asymptomatic Infection or Prior to Symptom Onset?
Patrozou, E., & Mermel, L. A. (2009) · Public Health Reports · doi:10.1177/003335490912400205 · Cited by 123
Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation
Burls, A., Clark, W. K., Stewart, T., Preston, C., Bryan, S., Jefferson, T., & Fry-Smith, A. (2002) · Health Technology Assessment · doi:10.3310/hta6090 · Cited by 121
Self-citationHuić, M., Marušić, M., & Marušić, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025258 · Cited by 115
Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis
Burch, J., Corbett, M. S., Stock, C., Nicholson, K. G., Elliot, A. J., Duffy, S., Westwood, M. E., Palmer, S., & Stewart, L. A. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70199-9 · Cited by 114
Hernán, M. Á., & Lipsitch, M. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir400 · Cited by 107
Opening up data at the European Medicines Agency
Gøtzsche, P. C., & Jorgensen, A. W. (2011) · BMJ · doi:10.1136/bmj.d2686 · Cited by 106
VIRAL SHEDDING IN CHILDREN WITH INFLUENZA VIRUS INFECTIONS TREATED WITH NEURAMINIDASE INHIBITORS
Sato, M., Hosoya, M., Kato, K., & Suzuki, H. (2005) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000180976.81055.ce · Cited by 106
Murphy, K. R., Eivindson, A., Pauksens, K., Stein, W. J., Tellier, G., Watts, R. W., ophonte, P. L., Sharp, S. J., & Loeschel, E. (2000) · Clinical Drug Investigation · doi:10.2165/00044011-200020050-00005 · Cited by 105
Lee, N. L. S., Hui, D. S. C., Zuo, Z., Ngai, K. L. K., Lui, G. C.-Y., Wo, S., Tam, W., Chan, M. C. W., Wong, B. C. K., Wong, R. Y. K., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit597 · Cited by 99
Oral Oseltamivir in Human Experimental Influenza B Infection
Hayden, F. G., Jennings, L., Robson, R. A., Schiff, G. M., Jackson, H. C., Rana, B., McClelland, G., Ipe, D., Roberts, N. A., & Ward, P. (2000) · Antiviral Therapy · doi:10.1177/135965350000500305 · Cited by 96
Johnston, S. L., Ferrero, F., García‐García, M. L., & Dutkowski, R. T. (2005) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000154322.38267.ce · Cited by 95
Searching for unpublished trials in Cochrane reviews may not be worth the effort
van Driel, M., Sutter, A. D., Maeseneer, J. D., & Christiaens, T. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.09.010 · Cited by 95
Kawai, N., Ikematsu, H., Iwaki, N., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/429241 · Cited by 92
Rodgers, M., Brown, J. V. E., Heirs, M. K., Higgins, J. P. T., Mannion, R., Simmonds, M. C., & Stewart, L. A. (2013) · BMJ · doi:10.1136/bmj.f3981 · Cited by 86
Neuraminidase inhibitors--the story behind the Cochrane review
Doshi, P. (2009) · BMJ · doi:10.1136/bmj.b5164 · Cited by 86
Self-citationMassarella, J. W., He, G. Z., Dorr, A. E., Nieforth, K. A., Ward, P., & Brown, A. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022009567 · Cited by 85
Vedula, S. S., Li, T., & Dickersin, K. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001378 · Cited by 85
Short-Term Treatment with Zanamivir to Prevent Influenza: Results of a Placebo-Controlled Study
Kaiser, L., Henry, D. C., Flack, N., Keene, O. N., & Hayden, F. G. (2000) · Clinical Infectious Diseases · doi:10.1086/313696 · Cited by 84
Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks
Schilling, M. L. (1998) · Vaccine · doi:10.1016/s0264-410x(98)00141-8 · Cited by 82
Comprehending Behavioral Statistics
Hurlburt, R. T. (1993) · Medical Entomology and Zoology · Cited by 81
Ioannidis, J. P. A., & Karassa, F. B. (2010) · BMJ · doi:10.1136/bmj.c4875 · Cited by 81
Kawai, N., Ikematsu, H., Iwaki, N., Maeda, T., Kanazawa, H., Kawashima, T., Tanaka, O., Yamauchi, S., Kawamura, K., Nagai, T., et al. (2007) · Journal of Infection · doi:10.1016/j.jinf.2007.09.002 · Cited by 80
Doshi, P., & Jefferson, T. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002496 · Cited by 79
Self-citationBoivin, G., Goyette, N., Hardy, I., Aoki, F. Y., Wagner, A., & Trottier, S. (2000) · The Journal of Infectious Diseases · doi:10.1086/315392 · Cited by 76
Li, C., Yu, Q., Ye, Z., Sun, Y., He, Q., Li, X.-M., Zhang, W., Luo, J., Gu, X., Zheng, X., et al. (2007) · Cell Research · doi:10.1038/cr.2007.27 · Cited by 75
Ebell, M., Call, M., & Shinholser, J. (2013) · Family Practice · doi:10.1093/fampra/cms059 · Cited by 74
Influenza activity--United States, 2012-13 season and composition of the 2013-14 influenza vaccine.
(2013) · PubMed Central · Cited by 73
Safety and pharmacokinetics of oseltamivir at standard and high dosages
Dutkowski, R. T., Smith, J., & Davies, B. E. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.12.023 · Cited by 69
Complications: tracking down the data on oseltamivir
Cohen, D. (2009) · BMJ · doi:10.1136/bmj.b5387 · Cited by 69
Jefferson, T., Pietrantonj, C. D., Debalini, M. G., Rivetti, A., & Demicheli, V. (2009) · BMJ · doi:10.1136/bmj.b354 · Cited by 63
Self-citationNeuraminidase inhibitors for preventing and treating influenza in healthy adults
Jefferson, T., Jones, M., Doshi, P., Mar, C. D., Dooley, L., & Foxlee, R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001265.pub3 · Cited by 62
Self-citationPeng, A., Milleri, S., & Stein, D. S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.7.1974-1976.2000 · Cited by 60
Sato, M., Saito, R., Sato, I., Tanabe, N., Shobugawa, Y., Sasaki, A., Li, D., Suzuki, Y. A., Sato, M., Sakai, T., et al. (2008) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.214.113 · Cited by 60
Rethinking credible evidence synthesis
Doshi, P., Jones, M., & Jefferson, T. (2012) · BMJ · doi:10.1136/bmj.d7898 · Cited by 60
Self-citationLaForce, C., Man, C. Y., Henderson, F. W., McElhaney, J. E., Hampel, F. C., Bettis, R. B., Kudule, L., Harris, J., Yates, P., Tisdale, M., et al. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.08.023 · Cited by 57
Gravenstein, S., Drinka, P. J., Osterweil, D., Schilling, M. L., Krause, P. F., Elliott, M. J., Shult, P. A., Ambrozaitis, A., Kandel, R., Binder, E. F., et al. (2005) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2005.08.006 · Cited by 55
Falagas, M. E., Koletsi, P. K., Vouloumanou, E. K., Rafailidis, P. I., Kapaskelis, A. M., & Rello, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq158 · Cited by 55
Blumentals, W. A., & Song, X. A. (2007) · PubMed Central · Cited by 54
How useful are unpublished data from the Food and Drug Administration in meta-analysis?
MacLean, C. H., Morton, S. C., Ofman, J. J., Röth, E., & Shekelle, P. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00520-6 · Cited by 54
Matsumoto, K., Ogawa, N., Nerome, K., Numazaki, Y., Kawakami, Y., Shirato, K., Arakawa, M., Kudoh, S., Shimokata, K., Nakajima, S., et al. (1999) · Antiviral Therapy · doi:10.1177/135965359900400202 · Cited by 52
Cass, L., Gunawardena, K. A., MacMahon, M., & Bye, A. (2000) · Respiratory Medicine · doi:10.1053/rmed.1999.0718 · Cited by 49
Moore, M. L., Michael, H., Zhou, W., Goleniewska, K., O’Neal, J. F., Higginbotham, J. N., & Peebles, R. S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2651 · Cited by 47
Oseltamivir and Abnormal Behaviors
Yorifuji, T., Suzuki, E., & Tsuda, T. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a3d3f6 · Cited by 47
Matsumoto, K., Ogawa, N., Nerome, K., Numazaki, Y., Kawakami, Y., Shirato, K., Arakawa, M., Kudoh, S., Shimokata, K., Nakajima, S., et al. (1999) · PubMed · Cited by 47
Schentag, J. J., Hill, G., Chu, T., & Rayner, C. R. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007299761 · Cited by 46
Hama, R. (2008) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-2008-0431 · Cited by 46
Self-citationEnsuring safe and effective drugs: who can do what it takes?
Jefferson, T., Doshi, P., Thompson, M., Heneghan, C. J., & C. A. R. I. Group (2011) · BMJ · doi:10.1136/bmj.c7258 · Cited by 43
Self-citationKashiwagi, S., Watanabe, A., Ikematsu, H., Awamura, S., Okamoto, T., Uemori, M., & Ishida, K. (2013) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-013-0622-9 · Cited by 43
Kashiwagi, S., Kudoh, S., Watanabe, A., & Yoshimura, I. (2000) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi1970.74.1044 · Cited by 41
Ambrozaitis, A., Gravenstein, S., van Essen, G. A., Rubinstein, E., Balčiūnienė, L., Stiklerytė, A., Crawford, C., Elliott, M. J., & Shult, P. A. (2005) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2005.08.007 · Cited by 41
Takahashi, E., Kataoka, K., Fujii, K., Chida, J., Mizuno, D., Fukui, M., Ito, H., Fujihashi, K., & Kido, H. (2010) · Microbes and Infection · doi:10.1016/j.micinf.2010.04.013 · Cited by 40
Puhakka, T., Lehti, H., Vainionpää, R., Jormanainen, V. J., Pulkkinen, M., Sharp, S. J., Kerr, C., Dempsey, M. H., Ring, C., Ward, C., et al. (2003) · Scandinavian Journal of Infectious Diseases · doi:10.1080/0036554021000026981 · Cited by 39
Aoki, F. Y., Fleming, D., Griffin, A. D., Lacey, L. A., & Edmundson, S. (2000) · PharmacoEconomics · doi:10.2165/00019053-200017020-00007 · Cited by 37
Oseltamivir, an Anti-influenza Virus Drug, Produces Hypothermia in Mice
Ono, H., Nagano, Y., Matsunami, N., Sugiyama, S., Yamamoto, S., & Tanabe, M. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.638 · Cited by 36
Possible harms of oseltamivir--a call for urgent action.
Jefferson, T., Jones, M., Doshi, P., & Mar, C. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61804-3 · Cited by 36
Self-citationA pandemic response to a disease of predominantly seasonal intensity
Kelly, H. A. (2010) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2010.tb03423.x · Cited by 36
Unpublished data can be of value in systematic reviews of adverse effects: methodological overview
Golder, S., Loke, Y. K., & Bland, M. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.02.009 · Cited by 35
Missing clinical trial data: setting the record straight
Godlee, F., & Loder, E. (2010) · BMJ · doi:10.1136/bmj.c5641 · Cited by 34
Boost of mucosal secretory immunoglobulin A response by clarithromycin in paediatric influenza
Sawabuchi, T., Suzuki, S. O., IWASE, K., Chika, I. T. O., Mizuno, D., Togari, H., WATANABE, I., Talukder, S. R., Chida, J., & Kido, H. (2009) · Respirology · doi:10.1111/j.1440-1843.2009.01639.x · Cited by 34
Winther, B., Block, S. L., Reisinger, K. S., & Dutkowski, R. T. (2010) · International Journal of Pediatric Otorhinolaryngology · doi:10.1016/j.ijporl.2010.03.024 · Cited by 34
Why don't we have all the evidence on oseltamivir?
Godlee, F., & Clarke, M. (2009) · BMJ · doi:10.1136/bmj.b5351 · Cited by 33
Bettis, R. B., Iacuzio, D. A., Jung, T., Fuchs, R., Aultman, R., & Gyldmark, M. (2006) · Clinical Drug Investigation · doi:10.2165/00044011-200626060-00004 · Cited by 30
Zanamivir Treatment Is Equally Effective for Both Influenza A and Influenza B
Kawai, N., Ikematsu, H., Iwaki, N., Tanaka, O., Yamanishi, Y., Hirotsu, N., & Kashiwagi, S. (2007) · Clinical Infectious Diseases · doi:10.1086/518385 · Cited by 30
Kashiwagi, S., Kudoh, S., WATANABE, A., & Yoshimura, I. (2000) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi1970.74.1062 · Cited by 30
Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial)
Thorne-Humphrey, L. M., Goralski, K. B., Slayter, K., Hatchette, T. F., Johnston, B., McNeil, S., & (The 2009 OPTIMO Study Group) (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr257 · Cited by 29
How influenza’s neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency
Bhatia, A., & Kast, R. E. (2006) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-006-0055-x · Cited by 26
Anekthananon, T., Pukrittayakamee, S., Ratanasuwan, W., Jittamala, P., Werarak, P., Charunwatthana, P., Suwanagool, S., Lawpoolsri, S., Stepniewska, K., Sapchookul, P., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks418 · Cited by 21
Hama, R., Jones, M., Okushima, H., Kitao, M., Noda, N., Hayashi, K., & Sakaguchi, K. (2011) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-2011-0545 · Cited by 20
Self-citationThe effect of zanamivir treatment on the early immune response to influenza vaccination
Cox, R. J., Mykkeltvedt, E., Sjursen, H., & Haaheim, L. R. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00219-5 · Cited by 20
Antivirals for influenza in healthy adults
Smith, J., Dutkowski, R. T., & Ward, P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68683-2 · Cited by 17
Ono, H., Iwajima, Y., Nagano, Y., Chazono, K., Maeda, Y., Ohsawa, M., & Yamamoto, S. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12058 · Cited by 17
Pukrittayakamee, S., Jittamala, P., Stepniewska, K., Lindegårdh, N., Chueasuwanchai, S., Leowattana, W., Phakdeeraj, A., Permpunpanich, S., Hanpithakpong, W., Ngum, W. P., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00159-11 · Cited by 14
Does Oseltamivir Really Reduce Complications of Influenza?
Cochrane Neuraminidase Inhibitors Review Team (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir706 · Cited by 13
What can we learn from observational studies of oseltamivir to treat influenza in healthy adults?
Freemantle, N., & Calvert, M. (2009) · BMJ · doi:10.1136/bmj.b5248 · Cited by 13
Neuropsychiatric Adverse Events and Oseltamivir for Prophylaxis
Jones, M., Hama, R., Jefferson, T., & Doshi, P. (2012) · Drug Safety · doi:10.1007/bf03262007 · Cited by 12
Self-citationAdoption of Global Agenda on Influenza--Part II.
(2002) · PubMed · Cited by 10
High Doses of Oseltamivir Phosphate Induce Acute Respiratory Arrest in Anaesthetized Rats
Kimura, S., Niwa, Y., Iwajima, Y., Nagano, Y., Yamamoto, S., Ohi, Y., Maeda, Y., Kurono, Y., Ono, H., & Haji, A. (2012) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2012.00889.x · Cited by 9
Dharan, N. J., Fry, A. M., Kieke, B. A., Coleman, L. A., Meece, J. K., Vandermause, M., Gubareva, L. V., Klimov, A. I., & Belongia, E. A. (2011) · Influenza and Other Respiratory Viruses · doi:10.1111/j.1750-2659.2011.00312.x · Cited by 8
Global agenda on influenza--adopted version. Part I.
(2002) · PubMed · Cited by 5
龙芸, 蔡柏蔷, 王孟昭, & 朱元珏 (2003) · 中华医学杂志:英文版 · Cited by 3
Research works printed but not linked: 6
- Ambrozaitis, 2001, Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population, Journal of the American Geriatrics Society, 49, 130
- 201, Influenza activity - United States and worldwide, June 13-September 25, 2010, Morbidity and Mortality Weekly Report, 59, 1270
- The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) M4: the common technical document http://www.ich.org/products/ctd.html
- Jack, Cost of WHO's proposed purchase of flu drugs questioned, Financial Times (Asia Ed1), 2
- Lefebvre, 2011, Chapter 6: Searching for studies
- Smith, 2009, Point-by-point response from Roche to BMJ questions, BMJ, 339, b5374, 10.1136/bmj.b5374 · doi:10.1136/bmj.b5374
Cited by
Increasing value and reducing waste: addressing inaccessible research
Chan, A.-W., Song, F., Vickers, A., Jefferson, T., Dickersin, K., Gøtzsche, P. C., Krumholz, H. M., Ghersi, D., & van der Worp, H. B. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62296-5 · Cited by 887
Self-citationRespiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment
Griffiths, C., Drews, S. J., & Marchant, D. J. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-16 · Cited by 586
Influenza virus-induced lung injury: pathogenesis and implications for treatment
Herold, S., Becker, C., Ridge, K. M., & Budinger, G. R. S. (2015) · European Respiratory Journal · doi:10.1183/09031936.00186214 · Cited by 503
Jefferson, T., Jones, M., Doshi, P., Spencer, E. A., Onakpoya, I., & Heneghan, C. J. (2014) · BMJ · doi:10.1136/bmj.g2545 · Cited by 447
Self-citationNeuraminidase inhibitors for preventing and treating influenza in adults and children
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Hama, R., Thompson, M. J., Spencer, E. A., Onakpoya, I. J., Mahtani, K. R., Nunan, D., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008965.pub4 · Cited by 382
Self-citation
Metadata
- Authors
- Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Heneghan, C. J., Hama, R., & Thompson, M. J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2012-01-18
- Volume
- 1
- Pages
- CD008965-CD008965
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2412668936
- Cited by
- 594
- References
- 161
- Type
- reference entry
- Language
- en
- Update notices
- new_version (2014-04-10)
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.